EDIT editasmedicine.com: Operating Profitability

Public company logo of Editas Medicine, Inc. (EDIT)

Editas Medicine, Inc. (EDIT) is betting on the monetization of CRISPR patents and reni-cel therapy. The operating margin snapshot demonstrates profitability dynamics, where the value -167.00 captures this metric. The company is minimizing risks by developing treatments for blood and vision disorders. An active R&D pipeline is currently focused on preparing breakthrough data regarding the application of Cas12a technology.

EDIT: Editas Medicine Inc Operating Return on Sales 07/04/2022 - 11/20/2026

EDIT (editasmedicine.com): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
- company stock capitalization data:
General company analysis:Editas Corp, EDIT
Finished products of Editas Medicine, Inc.

Conservative capital demands absolute transparency regarding operational efficiency to assess business sustainability. This indicator determines the portion of revenue remaining after covering all production costs before taxes and interest payments. For Editas Medicine, Inc. (EDIT), this metric represents the ability to monetize inelastic demand for unique CRISPR technology. High pricing power in gene editing should convert into profitability growth. The history of operating margin changes clearly demonstrates this process.

Analysis of competing companies

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|TXG - Operating Profitability Margin|Operating Margin NTLA|Profitability of Operations Stoke Therapeutics|Operating Profitability BioLife Solutions BLFS|Wave Life Sciences (WVE) - Operating Return on Sales|Maze Therapeutics, Inc. - Operating Margin|Profitability of Operations Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operating Profitability|TSHA: Operating Profit Ratio|Operating Profitability uniQure Pharma|MGTX - Operating Profitability Margin|Operating Margin RGNX|Operating Profitability SLDB (Solid Biosciences)|Ocugen Corp - Operating Sales Margin|PACB: Return on Sales by Operating Profit|benitec.com - Operating Margin|DSGN - Operating Margin|RCKT: Operating Margin|FDMT (4D Molecular Therapeutics Inc) - Operating Profitability|Operating Sales Margin LXEO|Operating Profitability KRRO|Operating Margin SLN|ProQR Therapeutics - Return on Sales by Operating Profit|Operating Margin CDXS (Codexis, Inc.)|SGMO: Return on Sales by Operating Profit|Nautilus Biotechnology - Operating Margin|Operating Profit Rate MGX (Metagenomi, Inc)|DTIL: Operating Margin|GBIO: Operating Profit Ratio|Operating Profitability Boundless Bio Inc.|Operating Sales Margin Exicure (XCUR)|Operating Margin IMNN|PHIO (Phio Pharmaceuticals Corp.) - Operating Profit Rate|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability